Plasma folate, vitamin B12, and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia: A case-control study

Gerontology

Volumn 47, Issue 6, 2001, Pages 324-329

  Postiglione, Alfredo ^a   Milan, Graziella ^a   Ruocco, Antonio ^a   Gallotta, Giovanni ^a   Guiotto, Giovanna ^a   Di Minno, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Alzheimer's disease; Folate; MTHFR gene; Plasma homocysteine; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION FUNCTION; DIET SUPPLEMENTATION; DISEASE DURATION; DISEASE SEVERITY; EVALUATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLIC ACID; GENETIC MARKERS; HOMOCYSTEINE; HUMANS; LOGISTIC MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; PROBABILITY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; VITAMIN B 12;

EID: 0035205173     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052822     Document Type: Article

References (25)

1. Brain infarction and the clinical expression of Alzheimer disease
2. Homocysteine and thrombotic disease
3. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial thrombosis
4. Homocysteine and Alzheimer's disease
5. Serum cobalamin and methylmalonic acid in Alzheimer dementia
6. Prevalence of cobalamin deficiency in the Framingham elderly population
7. Folate status, vascular disease and cognition in elderly Canadian
8. 12, and serum total homocysteine levels in confirmed Alzheimer disease
9. 12 and cognitive impairment in patients with Alzheimer's disease
10. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
11. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease
12. Plasma total homocysteine, B vitamins and risk of coronary atherosclerosis
13. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
14. Methylenetetrahydrofolate reductase C667T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: Evidence for an important genetic-environmental interaction
15. Elevated total plasma homocysteine and 677C→T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease
16. Total serum homocysteine in senile dementia of Alzheimer type
17. ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and Alzheimer's dementia
18. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): Its frequency and impact on plasma homocysteine concentration in different European populations
19. 12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methyelenetetrahydrofolate reductase (MTHFR) gene: A case-control study of patients with early-onset thrombotic events
20. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease
21. Neurochemical characterization of excitotoxin lesions in the cerebral cortex
22. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor
23. 12 and behavioural and psychological symptoms in Alzheimer's disease
24. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis
25. 12: Effects of replacement therapy on dementia